Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | UGT2B7 | P16662 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1824549 | 1.00 | MEN1 (0.42) | MEN1KMT2AUGT2B7ALDH1A1PTGS1 | |
| SCHEMBL2795994 | 1.00 | MEN1 (0.42) | MEN1KMT2AUGT2B7ALDH1A1PTGS1 | |
| SCHEMBL2832592 | 0.82 | PTGS1 (0.65) | MEN1KMT2AALDH1A1PTGS1CYP2D6 | |
| SCHEMBL1825924 | 0.82 | PTGS1 (0.53) | MEN1KMT2AALDH1A1PTGS1CA1 | |
| SCHEMBL1826859 | 0.82 | L3MBTL1 (0.39) | MEN1KMT2AALDH1A1PTGS1CA1 | |
| SCHEMBL1825973 | 0.81 | CA1 (0.39) | ALDH1A1PTGS1CA1CA2CA9 | |
| SCHEMBL2053885 | 0.81 | CA1 (0.39) | MEN1KMT2AALDH1A1PTGS1CA1 | |
| SCHEMBL1824420 | 0.81 | HDAC4 (0.49) | ALDH1A1PTGS1CA1CA2CA9 | |
| SCHEMBL2025338 | 0.81 | CA1 (0.39) | MEN1KMT2AALDH1A1PTGS1CA1 | |
| SCHEMBL2800774 | 0.81 | CA1 (0.39) | MEN1KMT2AALDH1A1PTGS1CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130096337-A1 | Process for Preparation of Optically Active Compounds using Transfer Hydrogenation | NOVARTIS AG (CH) | 2013-04-18 | — | — | US | claimed |
| US-8415508-B2 | Process for the preparation of optically active compounds using transfer hydrogenation | NOVARTIS AG (CH) | 2013-04-09 | — | — | US | claimed |
| US-20100168229-A1 | Process for the preparation of optically active compounds using transfer hydrogenation | NOVARTIS AG (CH) | 2010-07-01 | — | — | US | claimed |
| US-8637713-B2 | Process for preparation of optically active compounds using transfer hydrogenation | NOVARTIS AG (CH) | 2014-01-28 | — | — | US | disclosed |
| US-20130096337-A1 | Process for Preparation of Optically Active Compounds using Transfer Hydrogenation | NOVARTIS AG (CH) | 2013-04-18 | — | — | US | disclosed |
| US-8415508-B2 | Process for the preparation of optically active compounds using transfer hydrogenation | NOVARTIS AG (CH) | 2013-04-09 | — | — | US | disclosed |
| US-20100168229-A1 | Process for the preparation of optically active compounds using transfer hydrogenation | NOVARTIS AG (CH) | 2010-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130096337-A1 | Process for Preparation of Optically Active Compounds using Transfer Hydrogenation | SPR, ACHE, QDPR | MEN1 2309/4885KMT2A 1371/4885UGT2B7 304/4885 |
| US-20100168229-A1 | Process for the preparation of optically active compounds using transfer hydrogenation | SPR, ACHE, QDPR | MEN1 2459/4885KMT2A 1129/4885UGT2B7 388/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.